Cellular and Molecular Mechanisms of Chemoresistance for Gastric Cancer
Zonglin Li,Xingming Shu,Xin Liu,Qiuyun Li,Yifu Hu,Bingbing Jia,Min Song
DOI: https://doi.org/10.2147/ijgm.s473749
IF: 2.145
2024-09-01
International Journal of General Medicine
Abstract:Zonglin Li, 1, &ast Xingming Shu, 1, &ast Xin Liu, 1 Qiuyun Li, 2 Yifu Hu, 2 Bingbing Jia, 2 Min Song 3 1 Department of General Surgery (Gastrointestinal Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China; 2 Grade 2023, Clinical Medicine College, Southwest Medical University, Luzhou, People's Republic of China; 3 Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Min Song, Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China, Tel +8615883059785, Email Gastric cancer (GC) is one of the most common malignant tumors in the digestive tract, and chemotherapy plays an irreplaceable role in the comprehensive treatment of GC. However, chemoresistance makes it difficult for patients with GC to benefit steadily from chemotherapy in the long term, which ultimately leads to tumor recurrence, metastasis, and patient death. Elucidating the detailed mechanism of chemoresistance in GC and identifying specific therapeutic targets will help to solve the difficult problem of chemoresistance and improve the prognosis of patients with GC. This review summarizes and clarifies the cellular and molecular mechanisms underlying chemoresistance for GC. Keywords: gastric cancer, chemoresistance, cellular mechanisms, molecular mechanisms Gastric cancer (GC) is one of the most common malignant tumors in the digestive tract and seriously threatens human life and health. According to statistics, there were more than 1,089,103 new GC cases and 768,793 GC-induced deaths in 2020 worldwide, ranking fifth in morbidity and fourth in mortality among all cancer types. 1 In China, more than 509,421 new GC cases and 400,415 GC-induced deaths were recorded in 2022, ranking third in both morbidity and mortality among all cancer types. 2 At present, surgery is still the most important treatment for resectable GC. 3 Although comprehensive and individualized treatment based on surgery, chemoradiotherapy, targeted therapy and immunotherapy have been widely used in the treatment of GC, the overall efficacy is still not satisfactory. The 5-year survival rate of GC patients is only about 44.5%, and for patients with distant metastasis, it is only about 8.4%. 4 Chemotherapy plays an irreplaceable role in the comprehensive treatment of GC. However, chemoresistance makes it difficult for GC patients to benefit steadily from chemotherapy in the long term. According to related reports, the proportion of GC patients resistant to chemotherapy is about 46% to 80%. 5,6 For GC, chemotherapy regimens including XELOX (oxaliplatin plus capecitabine), SOX (S-1 plus oxaliplatin) and FOLFOX (oxaliplatin plus leucovorin and 5-fluorouracil) have been widely used in the clinical treatment. 7,8 But their efficacy is relatively limited and more than 95% GC patients fail chemotherapy with the progression of chemoresistance, which ultimately leads to tumor recurrence, metastasis, and patient death. 9 Chemoresistance of GC cells can be divided into primary drug resistance and acquired drug resistance, primary drug resistance means that GC cells possess genetic characteristics of natural drug resistance to various chemotherapeutic drugs, while acquired drug resistance refers to drug resistance produced by GC cells after long-term or repeated action of chemotherapeutic drugs. 10 Currently, most information about chemoresistance of GC cells is obtained from vitro experimental studies, and researchers have revealed a number of mechanisms of chemoresistance. 11–13 This review summarizes and clarifies the cellular and molecular mechanisms of chemoresistance for GC, aiming at providing a reference for solving the difficult problem of chemoresistance. Abnormally high expression of drug resistance related membrane proteins in cancer cells is one of the main causes of chemoresistance. The basic mechanism is that membrane proteins pump intracellular chemotherapeutic drugs out of the cells through an active energy-consuming mode or keep the drugs in membranous organelles. Thus, the drug concentration in cancer cells can be significantly reduced or their distribution can be effectively changed, leading to drug resistance in cancer cells. 14 This type of membrane proteins is mainly ATP-mediated ABC family related cell membrane transporters, and the representative proteins are P-glycoprotein (P-gp) and multi-drug resistance-associated protein 1 (MRP1). 15 P-gp is an act -Abstract Truncated-
medicine, general & internal